Endocarditis medical therapy

	Endocarditis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Infective Endocarditis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications & Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease
Diagnosis and Follow-up
Medical Therapy
Intervention
Case Studies
Case #1
Endocarditis medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Endocarditis medical therapy
CDC onEndocarditis medical therapy
Endocarditis medical therapy in the news
Blogs on Endocarditis medical therapy
to Hospitals Treating Endocarditis medical therapy
Risk calculators and risk factors for Endocarditis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editors-in-Chief: Cafer Zorkun, M.D., Ph.D. [2]; Ahmed Zaghw, M.D. [3]

Overview

Blood cultures should be drawn prior to instituting antibiotics to identify the etiologic agent and to determine its antimicrobial susceptibility. Older antibiotics such as penicillin G, ampicillin, nafcillin, cefazolin, gentamycin, ceftriaxone, rifampin and vancomycin are the mainstays of therapy.

Timing of Initiation of Antibiotics

Antibiotic therapy for subacute or indolent disease can be delayed until results of blood cultures are known; in fulminant infection or valvular dysfunction requiring urgent surgical intervention, begin empirical antibiotic therapy promptly after blood cultures have been obtained.

Duration of Antibiotic Therapy

The duration for native valve endocarditis is often 4 weeks. For prosthetic valve endocarditis (including the presence of a valve ring), treatment should be continued for 6 to 8 weeks. For each infective agent, the preferred antimicrobial agent, dose, and duration is listed below.

Empirical Antibiotic Therapy

Antibiotic therapy for subacute hemodynamically stable disease, and in those who have received antibiotics recently can be delayed waiting for the results of blood cultures, as this delay allows an additional blood cultures without the confounding effect of empiric treatment, which is very important in determining the causing pathogens.^[1]

On the other hand, the rapid progression of acute cases necessitate the start of empirical treatment antibiotic therapy once the blood cultures have been collected.

Empirical therapy is needed for all likely pathogens, certain antibiotic agents, including aminoglycosides, is preferably avoided for its toxic effects.

Clinical course of infection beside the epidemiological features should be considered upon selecting empirical treatment regimen.

Consultation with an infectious disease specialist for the selection of one of the antibiotic regimens is recommended (see therapy for culture-negative endocarditis). ^[2]

Treatment Based Upon Infectious Agent^[3]

Streptococci

Native Valve Endocarditis Caused by Viridans Group Streptococci and Streptococcus bovis

Viridans Group Streptococci and Streptococcus bovis Highly Penicillin-Susceptible

Native Valve Endocarditis Caused by Highly Penicillin-Susceptible Viridans Group Streptococci and Streptococcus bovis
Preferred Regimen ( 4 wks )
Adult dose
▸ Penicillin G sodium † 12–18 million U/24 h IV either continuously or in 4-6 equally divided doses x 4 Wks OR ▸ Ceftriaxone sodium 2 g/24 h IV/IM in 1 dose x 4 Wks
Pediatric dose ₳
▸ Penicillin G sodium 200 000 U/kg q24h IV either continuously or in 4-6 equally divided doses x 4 Wks OR ▸Ceftriaxone 100 mg/kg q24 h IV/IM in 1 dose x 4 Wks
Alternative Regimen ( 2 wks )
Adult dose
▸ Penicillin G sodium‡ 12–18 million U/24 h IV either continuously or in 6 equally divided doses x 2 Wks OR ▸ Ceftriaxone sodium 2 g/24 h IV/IM in 1 dose x 2 Wks
PLUS
▸ Gentamicin sulfate ฿ 3 mg/Kg per 24h 1 dose x 2 Wks\
Pediatric dose
▸ Penicillin G sodium 200 000 U/kg q24h IV in 4-6 equally divided doses x 2 Wks OR ▸Ceftriaxone 100 mg/kg q24 h IV/IM in 1 dose x 2 Wks
PLUS
▸ Gentamicin sulfate 3 mg/Kg per 24h 1 dose or 3 equally divided doses x 2 Wks
Alternative Regimen
Adult dose
▸ Vancomycin hydrochloride ¶ 15 mg/kg q12h IV x 4 Wks Doses should not to exceed 2 g/24 h unless concentrations in serum are inappropriately low
Pediatric dose
▸Vancomycin hydrochloride 40 mg/kg per 24 h IV in 2–3 equally divided doses

Minimum inhibitory concentration ≤ 0.12 μg/mL.

† Preferred in most patients >65 y or patients with impairment of 8th cranial nerve function or renal function.

₳ Pediatric dose should not exceed that of a normal adult.

‡ 2-wk regimen not intended for patients with known cardiac or extracardiac abscess or for those with creatinine clearance of <20 mL/min, impaired 8th cranial nerve function, or Abiotrophia, Granulicatella, or Gemella spp infection; gentamicin dosage should be adjusted to achieve peak serum concentration of 3-4 μg/mL and trough serum concentration of >1 μg/mL when 3 divided doses are used; nomogram used for single daily dosing.

¶ Vancomycin therapy recommended only for patients unable to tolerate penicillin or ceftriaxone; vancomycin dosage should be adjusted to obtain peak (1 h after infusion completed) serum concentration of 30–45 μg/mL and a trough concentration range of 10–15 μg/mL

฿ Other potentially nephrotoxic drugs (eg, nonsteroidal antiinflammatory drugs) should be used with caution in patients receiving gentamicin therapy. Although it is preferred that gentamicin (3 mg/kg) be given as a single daily dose to adult patients with endocarditis due to viridans group streptococci, as a second option, gentamicin can be administered daily in 3 equally divided doses.

Viridans Group Streptococci and Streptococcus bovis Relatively Penicillin Resistant (MIC >0.12 μg/mL- ≤ 0.5 μg/mL)

Native Valve Endocarditis Caused by Strains of Viridans Group Streptococci and Streptococcus bovis Relatively Resistant to Penicillin (MIC >0.12 μg/mL- ≤ 0.5 μg/mL))
Preferred Regimen
Adult dose
▸ Penicillin G sodium 24 million U/24 h IV either continuously or in 4–6 equally divided doses x 4 wks OR ▸ Ceftriaxone 2 g/24 h IV/IM in 1 dose x 4 wks
PLUS
▸ Gentamicin sulfate 3 mg/kg per 24 h IV/IM in 1 dose x 2 wks
Pediatric dose
▸ Penicillin G sodium 300 000 U/kg per 24 h IV in 4–6 equally divided doses OR ▸ Ceftriaxone 100 mg/kg per 24 h IV/IM in 1 dose
PLUS
▸ Gentamicin sulfate 3 mg/kg per 24 h IV/IM in 1 dose or equally divided doses
Alternative Regimen
Adult dose
▸ Vancomycin hydrochloride 30 mg/kg per 24 h IV in 2 equally divided doses x 4 wks
Pediatric dose
▸ Vancomycin hydrochloride 40 mg/kg per 24 h IV or in 2 or 3 equally divided doses

Prosthetic Valves Endocarditis or Other Prosthetic Material Caused by Viridans Group Streptococci and Streptococcus Bovis

Viridans Group Streptococci and Streptococcus bovis Penicillin-susceptible strain (MIC ≤ 0.12 μg/mL)

Penicillin-susceptible strain (MIC ≤ 0.12 g/mL)
Preferred Regimen
Adult dose
▸ Penicillin G sodium † 24 million U/24 h IV either continuously or in 4–6 equally divided doses x 6 wks OR ▸ Ceftriaxone 2 g/24 h IV/IM in 1 dose x 6 wks
WITH OR WITHOUT
▸ Gentamicin sulfate ‡ 3 mg/kg per 24 h IV/IM in 1 dose x 2 wks
Pediatric dose
▸ Penicillin G sodium 300 000 U/kg per 24 h IV in 4–6 equally divided doses OR ▸ Ceftriaxone 100 mg/kg IV/IM once daily
WITH OR WITHOUT
▸Gentamicin 3 mg/kg per 24 h IV/IM, in 1 dose or 3 equally divided doses
Alternative Regimen
Adult dose
▸ Vancomycin hydrochloride 30 mg/kg per 24 h IV in 2 equally divided doses x 6 wks
Pediatric dose
▸ 40 mg/kg per 24 h IV or in 2 or 3 equally divided doses

Dosages recommended are for patients with normal renal function.

† Penicillin or ceftriaxone together with gentamicin has not demonstrated superior cure rates compared with monotherapy with penicillin or ceftriaxone for patients with highly susceptible strain; gentamicin therapy should not be administered to patients with creatinine clearance of <30 mL/min.

‡ Although it is preferred that gentamicin (3 mg/kg) be given as a single daily dose to adult patients with endocarditis due to viridans group streptococci, as a second option, gentamicin can be administered daily in 3 equally divided doses.

Viridans Group Streptococci and Streptococcus bovis Penicillin relatively or fully resistant strain (MIC >0.12 μg/mL)

Penicillin relatively or fully resistant strain (MIC >0.12 >μg/mL))
Preferred Regimen
Adult dose
▸ Penicillin G sodium 24 million U/24 h IV either continuously or in 4–6 equally divided doses x 6 wks OR ▸ Ceftriaxone 2 g/24 h IV/IM in 1 dose x 6 wks
PLUS
▸ Gentamicin sulfate 3 mg/kg per 24 h IV/IM in 1 dose x 6 wks
Pediatric dose
▸ Penicillin G sodium 300 000 U/kg per 24 h IV in 4–6 equally divided doses
Alternative Regimen
Adult dose
▸ Vancomycin hydrochloride 30 mg/kg per 24 h IV in 2 equally divided doses x 6 wks
Pediatric dose
▸ Vancomycin hydrochloride 40 mg/kg per 24 h IV or in 2 or 3 equally divided doses

Viridans Group Streptococci and Streptococcus bovis Relatively Penicillin-Resistant Streptococci, MIC 0.2–0.5 µg/ml

Relatively Penicillin-Resistant Streptococci, MIC 0.2–0.5 µg/ml
Preferred Regimen
Adult dose
▸ Penicillin G potassium 24 million U/24 h IV either continuously or in 4–6 equally divided doses X 4 Wks OR ▸Ceftriaxone 2 g/24 h IV/IM in 1 dose
AND
▸ Gentamicin 3 mg/kg I.M. or I.V. daily in divided doses q. 8 hr X 2 Wks
Pediatric dose
▸ Penicillin G potassium 300 000 U/24 h IV in 4–6 equally divided doses X 4 Wks OR ▸ Ceftriaxone 100 mg/kg per 24 h IV/IM in 1 dose
AND
▸ Gentamicin 3 mg/kg per 24 h IV/IM in 1 dose or 3 equally divided doses X 2 Wks

Relatively Penicillin-Resistant Streptococci, (MIC > 0.5 µg/ml)

Relatively Penicillin-Resistant Streptococci, MIC > 0.5 µg/ml, consider Enterococcal regimen
Preferred Regimen
Adult dose
▸ Penicillin G potassium 24 million U/24 h IV either continuously or in 4–6 equally divided doses x 4 Wks
PLUS
▸ Gentamicin 3 mg/kg I.M. or I.V. daily in divided doses q. 8 hr x 2 Wks
Pediatric dose
▸ Penicillin G potassium 24 million U/24 h IV either continuously or in 4–6 equally divided doses x 4 Wks
PLUS
▸ Gentamicin 3 mg/kg I.M. or I.V. daily in divided doses q. 8 hr x 2 Wks

Unable to tolerate Penicillin or Ceftriaxone

Unable to tolerate Aqueous crystalline penicillin G sodium or Ceftriaxone
Preferred Regimen
Adult dose
▸ Vancomycin 30 mg/kg per 24 h IV in 2 equally divided doses not to exceed 2 g/24 h, unless serum concentrations are inappropriately low
Pediatric dose
▸ Vancomycin 40 mg/kg 24 h in 2 or 3 equally divided doses X 4 Wks

Enterococci

Native valve or prosthetic valve enterococcal endocarditis requires combination therapy with two antibiotics as the following:

Enterococci Strains Susceptible to Penicillin, Gentamicin, and Vancomycin

Enterococci Strains Susceptible to Penicillin, Gentamicin, and Vancomycin
Preferred Regimen
Adult dose
▸ Ampicillin 12 g/24 h I.V.in 6 equally divided doses x 4–6 Wks OR ▸Penicillin G sodium 18–30 million U. I.V. daily in 6 equally divided doses x 4–6 Wks
PLUS
▸Gentamicin sulfate 3 mg/kg per 24 h IV/IM in 3 equally divided doses x 4-6 Wks
Alternative Regimen
▸ Vancomycin 30 mg/kg I.V. daily in 2 equally divided doses x 6 Wks PLUS ▸Gentamicin sulfate 3 mg/kg per 24 h IV/IM in 3 equally divided doses x 6 Wks
Pediatric dose
▸ Ampicillin 300 mg/kg per 24 h IV in 4–6 equally divided doses; X 4–6 Wks OR ▸Penicillin G sodium 300 000 U/kg per 24 h IV in 4–6 equally divided doses X 4–6 Wks
PLUS
▸Gentamicin sulfate 3 mg/kg per 24 h IV/IM in 3 equally divided doses X 4-6 Wks
OR (in penicillin hypersensitivity)
▸ Vancomycin 30 mg/kg I.V. daily in divided doses q. 12 hour X 4–6 Wks PLUS ▸Gentamicin sulfate 3 mg/kg per 24 h IV/IM in 3 equally divided doses X 4-6 Wks

Enterococci Strains Susceptible to Penicillin, Streptomycin, and Vancomycin and Resistant to Gentamicin

Enterococci Strains Susceptible to Penicillin, Streptomycin, and Vancomycin and Resistant to Gentamicin
Preferred Regimen
Adult dose
▸ Ampicillin 12 g/24 h I.V.in 6 equally divided doses x 4–6 Wks OR ▸Penicillin G sodium 24 million U. I.V. continuously or in 6 equally divided doses x 4–6 Wks
PLUS
▸Streptomycin sulfate 15 mg/kg per 24 h IV/IM in 2 equally divided doses x 4-6 Wks
Alternative Regimen
▸ Vancomycin 30 mg/kg I.V. daily in 2 equally divided doses x 6 Wks PLUS ▸Streptomycin sulfate 15 mg/kg per 24 h IV/IM in 2 equally divided doses x 4-6 Wks
Pediatric dose
▸ Ampicillin 300 mg/kg per 24 h IV in 4–6 equally divided doses; X 4–6 Wks OR ▸Penicillin G sodium 300 000 U/kg per 24 h IV in 4–6 equally divided doses X 4–6 Wks
PLUS
▸Streptomycin sulfate 20–30 mg/kg per 24 h IV/IM in 2 equally divided doses
OR (in penicillin hypersensitivity)
▸ *Vancomycin 40 mg/kg per 24 h* IV in 2 or 3 equally divided doses X 4–6 Wks PLUS ▸Streptomycin sulfate 20–30 mg/kg per 24 h IV/IM in 2 equally divided doses

Enterococci Strains Resistant to Penicillin and Susceptible to Aminoglycoside and Vancomycin

β-Lactamase–producing strain
Preferred Regimen
Adult dose
▸ Ampicillin-sulbactam 12 g/24 h IV in 4 equally divided doses x 6 Wks PLUS ▸Gentamicin sulfate 3 mg/kg per 24 h IV/IM in 3 equally divided doses x 6 Wks
Pediatric dose
▸ Ampicillin-sulbactam 300 mg/kg per 24 h IV in 4 equally divided doses x 6 Wks PLUS ▸Gentamicin sulfate 3 mg/kg per 24 h IV/IM in 3 equally divided doses x 6 Wks
Alternative Regimen
▸Vancomycin hydrochloride 30 mg/kg per 24 h IV in 2 equally divided doses x 6 Wks PLUS ▸Gentamicin sulfate 3 mg/kg per 24 h IV/IM in 3 equally divided doses x 6 Wks
Pediatric dose
▸ Vancomycin hydrochloride 40 mg/kg per 24 h in 2 or 3 equally divided doses PLUS ▸Gentamicin sulfate 3 mg/kg per 24 h IV/IM in 3 equally divided doses x 6 Wks

Intrinsic penicillin resistance
Adult dose
▸Vancomycin hydrochloride 30 mg/kg per 24 h IV in 2 equally divided doses x 6 Wks PLUS ▸Gentamicin sulfate 3 mg/kg per 24 h IV/IM in 3 equally divided doses x 6 Wks
Pediatric dose
▸ Vancomycin hydrochloride 40 mg/kg per 24 h in 2 or 3 equally divided doses PLUS ▸Gentamicin sulfate 3 mg/kg per 24 h IV/IM in 3 equally divided doses x 6 Wks

Enterococci Strains Resistant to Penicillin, Aminoglycoside, and Vancomycin

E faecium
Adult dose
▸ Linezolid 1200 mg/24 h IV/PO in 2 equally divided doses x ≥8 Wks OR ▸Quinupristin-dalfopristin 22.5 mg/kg per 24 h IV in 3 equally divided doses x ≥ 8 Wks
Pediatric dose
▸ Linezolid 30 mg/kg per 24 h IV/PO in 3 equally divided doses ≥8 Wks OR ▸Quinupristin-dalfopristin 22.5 mg/kg per 24 h IV in 3 equally divided doses ≥8 Wks

E faecalis
Adult dose
Preferred Regimen
▸ Imipenem/cilastatin 2 g/24 h IV in 4 equally divided doses x ≥8 Wks PLUS ▸Ampicillin sodium 12 g/24 h IV in 6 equally divided doses x ≥ 8 Wks
Pediatric dose
▸ Imipenem/cilastatin 60–100 mg/kg per 24 h IV in 4 equally divided doses x ≥8 Wks PLUS ▸*Ampicillin sodium 300 mg/kg per 24* h IV in 4–6 equally divided doses x ≥ 8 Wks
Alternative Regimen
Adult dose
▸ Ceftriaxone sodium 4 g/24 h IV/IM in 2 equally divided doses x ≥8 Wks PLUS ▸Ampicillin sodium 12 g/24 h IV in 6 equally divided doses x ≥ 8 Wks
Pediatric dose
▸ Ceftriaxone sodium 100 mg/kg per 24 h IV/IM in 2 equally divided doses x ≥8 Wks PLUS ▸Ampicillin sodium 300 mg/kg per 24 h IV in 4–6 equally divided doses x ≥ 8 Wks

Staphylococci

Native Valve Endocarditis caused by Staphylococci in the Absence of Prosthetic Material

Staphylococci (Methicillin Susceptible) in the Absence of Prosthetic Material

Staphylococci (Methicillin Susceptible) in the Absence of Prosthetic Material
Preferred Regimen
Adult dose
▸ Nafcillin or Oxacillin † 12 g I.V. daily in equally divided doses x 6 Wks
PLUS (optional)
▸ Gentamicin sulfate ‡ 3 mg/kg per 24 h IV/IM in 2-3 equally divided doses x 3-5 days
Altenative Regimen( in non anaphylactoid Penicillin hypersensitivity)
▸ Cefazolin 6 g/ 24 h I.V. in 3 divided doses x 6 wks
PLUS (optional)
▸ Gentamicin 3 mg/kg per 24 h IV/IM in 2-3 equally divided doses x 3-5 days
Pediatrics dose
▸ Nafcillin or oxacillin 200 mg/kg per 24 h IV in 4–6 equally divided doses x 4-6 wks OR ( in non anaphylactoid Penicillin hypersensitivity) ▸Cefazolin 100 mg/kg per 24 h IV in 3 equally divided doses x 4-6 wks
AND (optional)
▸ Gentamicin 3 mg/kg per 24 h IV/IM in 3 equally divided doses

† Penicillin G 24 million U/24 h IV in 4 to 6 equally divided doses may be used in place of nafcillin or oxacillin if strain is penicillin susceptible (MIC ≤ 0.1 μg/mL) and does not produce β-lactamase.

‡ Gentamicin should be administered in close temporal proximity to vancomycin, nafcillin, or oxacillin dosing.

Staphylococci (Methicillin-resistant) with Penicillin G Anaphylactoid Hypersensitivity in the Absence of Prosthetic Material

Staphylococci (Methicillin-resistant) in the Absence of Prosthetic Material (in anaphylactoid Penicillin hypersensitivity)
Preferred Regimen
Adult dose
▸ Vancomycin 30 mg/kg per 24 h IV in 2 equally divided doses x 6 wks Adjust vancomycin dosage to achieve 1-h serum concentration of 30–45 > g/mL and trough concentration of 10–15 >g/mL
Pediatrics dose
▸ Vancomycin 40 mg/kg per 24 h IV in 2 or 3 equally divided doses x 6 wks

Prosthetic Valves Endocarditis or Other Prosthetic Material Caused by Staphylococci

Oxacillin-susceptible strains in the Presence of Prosthetic Material

Oxacillin-susceptible strains
Adult dose
▸ Nafcillin or oxacillin 2 g q4h IV x ≥6 weeks PLUS ▸ Rifampin 300 mg q8h IV/PO x ≥6 weeks PLUS ▸ Gentamicin 3 mg/kg per 24 h IV/IM in 2 or 3 equally divided doses x 2 weeks
Pediatric dose
▸Nafcillin or oxacillin 200 mg/kg per 24 h IV in 4–6 equally divided doses PLUS ▸Rifampin 20 mg/kg per 24 h IV/PO in 3 equally divided doses PLUS ▸Gentamicin 1 mg/kg q8h IV/IM

Oxacillin-resistant strains in the Presence of Prosthetic Material

Oxacillin-resistant strains
Adult dose
▸ Vancomycin 15 mg/kg q12h x ≥6 Wks PLUS ▸ Rifampin 300 mg q8h IV/PO x ≥6 Wks PLUS ▸ Gentamicin 3 mg/kg per 24 h IV/IM in 2 or 3 equally divided doses x 2 wks
Pediatric dose
▸ Vancomycin 40 mg/kg per 24 h IV in 2-3 equally divided doses x ≥6 wks PLUS ▸Rifampin 20 mg/kg per 24 h IV/PO in 3 equally divided doses x ≥6 wks PLUS ▸ Gentamicin 1 mg/kg q8h IV/IM x 2 Wks

HACEK Organisms

HACEK organisms are more indolent and the infection is less complicated.

Therapy for Both Native and Prosthetic Valve Endocarditis Caused by HACEK Microorganisms
Adult dose
▸ Ceftriaxone sodium † 2 g/24 h IV/IM in 1 dose x 4 weeks
OR
▸ Ampicillin- sulbactam ‡ 12 g/24 h IV in 4 equally divided doses x 4 weeks
OR
▸ Ciprofloxacin ‡¶ 500 mg q12h PO or 400 mg q12h IV x 4 weeks
Pediatric dose
▸ Ceftriaxone 100 mg/kg per 24 h IV/IM once daily
OR
▸Ampicillin- sulbactam 300 mg/kg per 24 h IV divided into 4 or 6 equally divided doses
OR
▸Ciprofloxacin 10-15 mg/kg q12h IV/PO

HACEK: Haemophilus parainfluenzae, H aphrophilus, Actinobacillus actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens, and Kingella kingae.

† Patients should be informed that IM injection of ceftriaxone is painful.

‡ Dosage recommended for patients with normal renal function.

¶ Fluoroquinolones are highly active in vitro against HACEK microorganisms. Published data on use of fluoroquinolone therapy for endocarditis caused by HACEK are minimal.

Culture Negative Endocarditis

Clinical course of infection beside the epidemiological features should be considered upon selecting treatment regimen.

Patients should be divided into 2 groups:

Patients Who Received Antibiotic Therapy Before the Blood Culture

Patients with acute clinical presentations with native valve infection: coverage of S. aureus should be followed as detailed in proven staphylococcal disease.

Patients with subacute presentation: antibiotic coverage for S. aureus, viridians group streptococci, and enterococci should be considered.

Antibiotics for HACEK group of organism also should be considered.

Symptomatic patients with prosthetic valve and culture negative infection within 1 year of valve replacement should receive vancomycin to cover the oxacillin-resistant staphylococci.

Symptomatic patients with prosthetic valve and culture negative infection within 2 months of valve replacement should also receive cefepime for gram negative bacilli coverage.

Symptomatic patients with prosthetic valve more than 1 year, the most likely causing organisms are oxacillin-susceptible staphylococci, viridians group streptococci, and enterococci. Antibiotic coverage for those organisms should be continued for at least 6 weeks.

Patients with Culture-Negative Endocarditis and Suspected Infection with Uncommon Endocarditis Pathogens

Examples of these pathogens include Bartonella species, Chlamydia species, Coxiella burnetii, Brucella species, Legionella species, Tropheryma whippleii, and non-Candida fungi.

The most common pathogens that have been reported with culture-negative endocarditis are Bartonella species, Coxiella burnetii, and Brucella species.

Antibiotic therapy for these pathogens should include aminoglycosides for at least 2 weeks.
Therapeutic regimens for Bartonella endocarditis based on the epidemiological risk and high index of suspicion.^[2]

Native Valve Culture Negative Endocarditis

Native valve
Adult dose
▸ Ampicillin-Sulbactam 3 g q6h IV x 4–6 wks PLUS ▸ Gentamicin sulfate 1 mg per kg q8h IV/IM x 4–6 wks
OR
▸ Vancomycin 15 mg per kg q12h IV x 4–6 wks PLUS ▸ Gentamicin sulfate 1 mg per kg q8h IV/IM x 4–6 wks PLUS Ciprofloxacin 500 mg q12h PO or 320 mg q12h IV x 4–6 wks
Pediatric dose
▸Ampicillin-Sulbactam300 mg per kg per 24 h IV in 4–6 equally divided doses PLUS ▸Gentamicin 1 mg per kg q8h IV/IM x 4–6 wks
OR
▸Vancomycin 32 mg per kg per 24 h in 2 or 3 equally divided doses x 4–6 wks PLUS ▸ Gentamicin sulfate 1 mg per kg q8h IV/IM x 4–6 wks PLUS ▸Ciprofloxacin 10-15 mg per kg q12h IV/PO x 4–6 wks

Prosthetic Valve Culture Negative Endocarditis

Prosthetic valve (early, ≤ 1y)
Adult dose
▸ Vancomycin 15 mg per kg q12h IV x 4-6 wks PLUS ▸ Gentamicin sulfate 1 mg per kg q8h IV/IM x 2wks PLUS ▸Cefepime 2 g q8h IV x 6 wks PLUS ▸ Rifampin 300 mg q8h PO/IV x 6 wks
Pediatric dose
▸Vancomycin 15 mg per kg q12h IV x 4-6 wks PLUS ▸Gentamicin 1 mg per kg q8h IV/IM x 2 wks PLUS ▸Cefepime 50 mg q8h IV x 6 wks PLUS ▸Rifampin 20 mg per kg per 24 h PO/IV in 3 equally divided doses x 6 wks
Prosthetic valve (late—greater than 1 y) (same regimens as for native valve endocarditis with addition of rifampin)
▸ Ampicillin-Sulbactam 3 g q6h IV x 4–6 wks PLUS ▸ Gentamicin sulfate 1 mg per kg q8h IV/IM x 4–6 wks PLUS ▸ Rifampin 300 mg q8h PO/IV x 6 wks
OR
▸ Vancomycin 15 mg per kg q12h IV x 4–6 wks PLUS ▸ Gentamicin sulfate 1 mg per kg q8h IV/IM x 4–6 wks PLUS ▸ Ciprofloxacin 500 mg q12h PO or 320 mg q12h IV x 4–6 wks PLUS ▸ Rifampin 300 mg q8h PO/IV x 6 wks

Bartonella Culture Negative Endocarditis

Suspected Bartonella, (culture negative)
▸ Ceftriaxone sodium 2 g per 24 h IV/IM in 1 dose x 6 wks PLUS ▸ Gentamicin sulfate 1 mg per kg q8h IV/IM x 2 wks
WITH / WITHOUT
▸ Doxycycline 100 mg per kg q12h IV/PO x 6 wks
Documented Bartonella, (culture positive)
Adult dose
▸ Doxycycline 100 mg q12h IV or PO x 6 wks PLUS ▸ Gentamicin sulfate 1 mg per kg q8h IV/IM x 2 wks
Pediatrics dose
▸Doxycycline 2–4 mg per kg per 24 h IV/PO in 2 equally divided doses PLUS ▸Gentamicin 1 mg per kg q8h IV/IM

References

↑ Braunwald, Eugene; Bonow, Robert O. (2012). Braunwald's heart disease : a textbook of cardiovascular medicin. Philadelphia: Saunders. ISBN 978-1-4377-2708-1.
↑ ^2.0 ^2.1 Baddour, LM.; Wilson, WR.; Bayer, AS.; Fowler, VG.; Bolger, AF.; Levison, ME.; Ferrieri, P.; Gerber, MA.; Tani, LY. (2005). "Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America". Circulation. 111 (23): e394–434. doi:10.1161/CIRCULATIONAHA.105.165564. PMID 15956145. Unknown parameter |month= ignored (help)
↑ Baddour Larry M., Wilson Walter R., Bayer Arnold S., Fowler Vance G. Jr, Bolger Ann F., Levison Matthew E., Ferrieri Patricia, Gerber Michael A., Tani Lloyd Y., Gewitz Michael H., Tong David C., Steckelberg James M., Baltimore Robert S., Shulman Stanford T., Burns Jane C., Falace Donald A., Newburger Jane W., Pallasch Thomas J., Takahashi Masato, Taubert Kathryn A. (2005). "Infective Endocarditis: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association-Executive Summary: Endorsed by the Infectious Diseases Society of America". Circulation. 111 (23): 3167–84. PMID 15956145.

Template:WH Template:WS

[1] Braunwald, Eugene; Bonow, Robert O. (2012). Braunwald's heart disease : a textbook of cardiovascular medicin. Philadelphia: Saunders. ISBN 978-1-4377-2708-1.

[Baddour-2005-2] 2.0 ^2.1 Baddour, LM.; Wilson, WR.; Bayer, AS.; Fowler, VG.; Bolger, AF.; Levison, ME.; Ferrieri, P.; Gerber, MA.; Tani, LY. (2005). "Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America". Circulation. 111 (23): e394–434. doi:10.1161/CIRCULATIONAHA.105.165564. PMID 15956145. Unknown parameter |month= ignored (help)

[Baddour-3] Baddour Larry M., Wilson Walter R., Bayer Arnold S., Fowler Vance G. Jr, Bolger Ann F., Levison Matthew E., Ferrieri Patricia, Gerber Michael A., Tani Lloyd Y., Gewitz Michael H., Tong David C., Steckelberg James M., Baltimore Robert S., Shulman Stanford T., Burns Jane C., Falace Donald A., Newburger Jane W., Pallasch Thomas J., Takahashi Masato, Taubert Kathryn A. (2005). "Infective Endocarditis: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association-Executive Summary: Endorsed by the Infectious Diseases Society of America". Circulation. 111 (23): 3167–84. PMID 15956145.

[1]

[2]

[3]